Navigation Links
KS-herpesvirus induces reprogramming of lymphatic endothelial cells to invasive mesenchymal cells
Date:12/14/2011

Human tumor viruses contribute to 15-20% of human cancers worldwide. Kaposi's sarcoma herpesvirus (KSHV) is an etiological agent for Kaposi's sarcoma (KS) and two other rare lymphoproliferative malignancies. KS is the most common cancer in HIV-infected untreated individuals and remains a primary cause of cancer deaths in many subequatorial African countries as a result of the AIDS pandemic. Researchers at the Institute of Biotechnology and Research Programs Unit (Genome-Scale Biology) at the University of Helsinki have discovered a novel viral oncogenesis mechanism in which KSHV oncogenes co-opt cellular signaling pathways and modify the cellular microenvironment more permissive for viral replication.

The findings by the group of Research Professor Pivi Ojala (Institute of Biotechnology, University of Helsinki) demonstrates the first lymphatic-specific endothelial-to-mesenchymal transition (EndMT) induced by a human tumor virus. The virus-induced EndMT can contribute to development of KS by giving rise to infected, invasive cells, and providing the virus a permissive cellular microenvironment for efficient spread of the virus.

"This information can be used for developing targeted therapies to prevent or at least slow down the progression of KS in immunosuppressed patients", Dr. Ojala says.

By developing a novel three-dimensional (3D) cell model to better mimic the in vivo microenvironment, the researchers show that KSHV induces transcriptional reprogramming of primary lymphatic endothelial cells (LEC) to mesenchymal cells via EndMT, a process implicated in promoting tumor growth and cell invasiveness. Mesenchymal markers were found co-distributed in the same cells with KSHV in primary KS tumor samples, suggesting that the 3D culture in this work succeeds in recapitulating the known heterogeneity of the cell types in KS tumors.

The results also reveal a key enzyme in cancer cell invasion, MT1-MMP, as a previously unrecognized signaling molecule downstream of Notch to induce EndMT. Moreover, the 3D KSHV-LEC transcriptome showed significant up-regulation of invasion related genes, that were found co-regulated in 3D KSHV-LECs and KS biopsies and suggesting that virus-induced EndMT may contribute to development of KS. The results further demonstrate that the 3D culture provides a permissive microenvironment for continuous viral replication and persistence, indicating the importance of virus-cell interactions for viral spread and thereby for oncogenesis.

"The unraveled molecular mechanisms can lead to identification of novel cellular targets for pharmacological control in virus-associated cancers", Dr. Ojala says.

This work is a collaboration between the research teams headed by Kaisa Lehti, Kari Alitalo, Lauri Aaltonen, and Sampsa Hautaniemi (all from University of Helsinki), Chris Boshoff (UCL Cancer Institute, University College London) and Adam Grundhoff (Heinrich Pette Institute-Leibniz Institute for Experimental Virology). The project involves scientists from two Academy of Finland National Centre of Excellence Programs, the Translational Genome-Scale Biology and Cancer Biology.


'/>"/>

Contact: Dr. Pivi Ojala
paivi.ojala@helsinki.fi
358-919-159-445
University of Helsinki
Source:Eurekalert

Related medicine news :

1. Single gene mutation induces endometrial cancer
2. CSHL scientists discover how a tumor suppressor induces senescence and staves off cancer
3. 2009 H1N1 vaccine safe and induces robust immune response in people with asthma
4. Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma
5. Discovery of a new reprogramming mechanism for tumor cells
6. Reprogramming brain cells important first step for new Parkinsons therapy
7. Pitt researchers discover gene mutation linked to lymphatic dysfunction
8. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
9. New study suggests stem cells sabotage their own DNA to produce new tissues
10. Attacking cancer cells with hydrogel nanoparticles
11. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: